PREDICTION OF DRUG INTERACTION IN VITRO -FOCUSING ON CYTOCHROME P-450 3A AND P-GLYCOPROTEIN-

体外药物相互作用的预测 - 重点关注细胞色素 P-450 3A 和 P-糖蛋白 -

基本信息

  • 批准号:
    10672153
  • 负责人:
  • 金额:
    $ 1.92万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 2000
  • 项目状态:
    已结题

项目摘要

Using cultured Caco-2 cell monolayers, we tried to investigate the involvement of cytochrome P-450 (CYP) 3A4 and P-glycoprotein (P-gp) and to predict drug interaction of orally administered agents in vitro. Probucol, a lipid-lowering drug, caused P-gp-independent suppression of cyclosporine A (a substrate of CYP3A4 and P-gp) transport across Caco-2 cell monolayers. Pretreatment with various inducers failed to augment the P-gp-induced drug extrusion into the apical side of Caco-2 cell monolayers. Microsome fraction from Caco-2 cells even treated with CYP inducers did not demonstrate oxidization of nifedipine which is mediated by CYP3A4.We thus performed ex vivo experiments using intact rats. Microsome fractions from the intestinal epithelium and liver showed oxidation of nifedipine (averaged production rate ; 35 and 160 pmol/min/mg protein, respectively). We constructed ex vivo intestinal perfusion system and examined the absorption and secretion of P-gp substrate drug. P-gp inhibitor (verapamil, ketoconazole) increased the transport of digoxin, a P-gp substrate, to the adventitial side, and decreased the secretion into the luminal perfusate, indicating that this system can be used to assess the involvement of P-gp in the drug absorption at the intestinal tract. Treatment with phenobarbital, a CYP inducer, increased CYP3A4 activity in the liver (+ 130 %), but not intestinal epithelium. Another inducer, rifampicin, elevated CYP3A4 activity in the intestinal epithelium (+ 32 %) without affecting the activity in the liver. Rifampicin also enhanced the P-gp activity in the intestine. These results from ex vivo study suggest that CYP inducers may cause tissue-specific induction of CYP or P-gp activity. The mechanism of tissue-specific induction of drug metabolism or drug extrusion needs to be clarified. It may be helpful to understand the mechanism of drug interaction.
利用培养的Caco-2细胞单层,我们试图研究细胞色素P-450(CYP)3A4和P-糖蛋白(P-gp)的参与,并预测口服药物在体外的药物相互作用。普罗布考是一种降脂药物,可抑制环孢素A(CyP3A4和P-gp的底物)通过Caco-2细胞单层的转运,这是P-gp非依赖性的。不同诱导剂均不能增强P-gp诱导的药物向Caco-2细胞单层顶端的排泄。Caco-2细胞的微丝体组分即使用CYP诱导剂处理,也没有表现出由CYP3A4介导的硝苯地平的氧化。肠上皮和肝脏的微粒体部分显示硝苯地平的氧化作用(平均产生速率分别为35和160pmol/min/mg蛋白)。建立体外肠道灌流系统,考察P-gp底物药物的吸收和分泌情况。P-gp抑制剂(维拉帕米、酮康唑)增加了P-gp底物地高辛向外膜的转运,减少了向腔灌流液的分泌,表明该系统可用于评价P-gp参与肠道药物吸收的作用。用CYP诱导剂苯巴比妥处理后,肝脏中的CYP3A4活性增加(+130%),但不能增加肠道上皮细胞的活性。另一种诱导剂利福平提高了肠上皮细胞色素P3A4的活性(+32%),但不影响肝脏的活性。利福平还能增强肠道P-gp活性。这些来自体外研究的结果表明,CYP诱导剂可能引起组织特异性的CYP或P-gp活性的诱导。组织特异性诱导药物代谢或药物排出的机制尚需阐明。这可能有助于理解药物相互作用的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUGIMOTO Koichi其他文献

SUGIMOTO Koichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUGIMOTO Koichi', 18)}}的其他基金

The novel molecular mechanism of membrane type1 matrix metallo proteinase(MT1-MMP) in vascular inflammation
膜1型基质金属蛋白酶(MT1-MMP)在血管炎症中的新分子机制
  • 批准号:
    22790718
  • 财政年份:
    2010
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of the mechanism of L-asparaginase to suppress the highly expressed eIF4E in NK-cell lymphoma
L-天冬酰胺酶抑制NK细胞淋巴瘤高表达eIF4E的机制分析
  • 批准号:
    21591222
  • 财政年份:
    2009
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of LOX-1-MT1-MMP axis in oxidized LDL-triggered endothelial dysfunction
LOX-1-MT1-MMP 轴在氧化 LDL 触发的内皮功能障碍中的作用
  • 批准号:
    20790538
  • 财政年份:
    2008
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Changes of cell cycle distribution and nuclear structure in NK cells by EBV infection
EBV感染后NK细胞细胞周期分布和核结构的变化
  • 批准号:
    14570997
  • 财政年份:
    2002
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Simulator for a Dynamic Analysis of a Multi-Rigid-body System
多刚体系统动态分析模拟器的开发
  • 批准号:
    14550238
  • 财政年份:
    2002
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Unified Theory for Kinematic and Dynamic Analysis System of Mechanisms
机构运动动力学分析系统统一理论
  • 批准号:
    11650269
  • 财政年份:
    1999
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

P-glycoprotein与Rack1和Src相互作用并促进耐药乳腺癌细胞侵袭转移的分子机制研究
  • 批准号:
    81472474
  • 批准年份:
    2014
  • 资助金额:
    85.0 万元
  • 项目类别:
    面上项目

相似海外基金

Inhibition or evasion of P-glycoprotein-mediated drug transport
抑制或逃避 P-糖蛋白介导的药物转运
  • 批准号:
    10568723
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
Physiological function of P-glycoprotein in sanctuary tissue barriers in teleosts
P-糖蛋白在硬骨鱼保护区组织屏障中的生理功能
  • 批准号:
    RGPIN-2020-04905
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Discovery Grants Program - Individual
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Undergraduate Summer Research
P-糖蛋白药物相互作用的研究 - 本科生暑期研究行政补充
  • 批准号:
    10810072
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Bacterial targeting of the P-glycoprotein/endocannabinoid axis for reducing intestinal inflammation in ulcerative colitis
细菌靶向 P-糖蛋白/内源性大麻素轴以减少溃疡性结肠炎的肠道炎症
  • 批准号:
    10537517
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Studies of P-glycoprotein drug interactions
P-糖蛋白药物相互作用的研究
  • 批准号:
    10661486
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Drug, Nucleotide, and Lipid Interactions with P-glycoprotein
药物、核苷酸和脂质与 P-糖蛋白的相互作用
  • 批准号:
    10672242
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Mechanisms of suicide attempts by loss of P-glycoprotein function in the blood-brain barrier
血脑屏障中 P-糖蛋白功能丧失导致自杀未遂的机制
  • 批准号:
    22K06774
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Studies of P-glycoprotein drug interactions
P-糖蛋白药物相互作用的研究
  • 批准号:
    10366914
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Equipment Purchase
P-糖蛋白药物相互作用研究-设备采购行政补充
  • 批准号:
    10795338
  • 财政年份:
    2022
  • 资助金额:
    $ 1.92万
  • 项目类别:
Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy
有机阴离子转运多肽 (OATP)、P-糖蛋白 (P-gp) 和乳腺癌抗性蛋白 (BCRP) 转运蛋白在乳腺癌治疗期间调节他莫昔芬反应
  • 批准号:
    452037
  • 财政年份:
    2021
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了